TrialModern rheumatology2016

Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.

Yoshiya Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.